ICUD-EAU international consultation on bladder cancer 2012: Chemotherapy for urothelial carcinoma - Neoadjuvant and adjuvant settings

European Urology

Volumn 63, Issue 1, 2013, Pages 58-66

  Sternberg, Cora N ^a   Bellmunt, Joaquim ^b   Sonpavde, Guru ^c   Siefker Radtke, Arlene O ^d   Stadler, Walter M ^e   Bajorin, Dean F ^f   Dreicer, Robert ^g   George, Daniel J ^h   Milowsky, Matthew I ⁱ   Theodorescu, Dan ^j   Vaughn, David J ^k   Galsky, Matthew D ^l   Soloway, Mark S ^m   Quinn, David I ⁿ  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^b HOSPITAL DEL MAR   (Spain)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g TAUSSIG CANCER INSTITUTE   (United States)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^k HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^l MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^m UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

ⁿ UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

more..

Author keywords

Adjuvant; Bladder cancer; Chemotherapy; Guidelines; Neoadjuvant; Recommendations

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GEMCITABINE; METHOTREXATE; PACLITAXEL; VINBLASTINE;

ADJUVANT THERAPY; BLADDER CANCER; BLADDER METASTASIS; CANCER CHEMOTHERAPY; COMORBIDITY; CONSULTATION; EVIDENCE BASED MEDICINE; HUMAN; MEDLINE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; SYSTEMATIC REVIEW; TRANSITIONAL CELL CARCINOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; HUMANS; NEOADJUVANT THERAPY; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84870571565     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.08.010     Document Type: Review

References (63)

1. D. Raghavan, W.U. Shipley, M.B. Garnick, P.J. Russell, and J.P. Richie Biology and management of bladder cancer N Engl J Med 322 1990 1129 1138
2. G. Dalbagni, E. Genega, and M. Hashibe Cystectomy for bladder cancer: a contemporary series J Urol 165 2001 1111 1116
3. J.P. Stein, G. Lieskovsky, and R. Cote Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients J Clin Oncol 19 2001 666 675
4. M.A. Ghoneim, M.M. el-Mekresh, M.A. el-Baz, I.A. el-Attar, and A. Ashamallah Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases J Urol 158 1997 393 399
5. H.W. Herr, and S.M. Donat Outcome of patients with grossly node positive bladder cancer after pelvic lymph node dissection and radical cystectomy J Urol 165 2001 62 64 discussion 64
6. J. Leissner, R. Hohenfellner, J.W. Thuroff, and H.K. Wolf Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis BJU Int 85 2000 817 823
7. Phillips B, Ball C, Sackett D, et al. Centre for Evidence-based Medicine - levels of evidence (March 2009). Centre for Evidence-based Medicine Web site. http://www.cebm.net/index.aspx?o=1025.
8. G. Sonpavde, and C.N. Sternberg Neoadjuvant systemic therapy for urological malignancies BJU Int 106 2010 6 22
9. H.I. Scher, and T.A. Splinter Neoadjuvant chemotherapy for invasive bladder cancer: future directions Semin Oncol 17 1990 635 638
10. T.A. Splinter, H.I. Scher, and L. Denis The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer - Genitourinary Group J Urol 147 1992 606 608
11. T.A. Splinter, D. Jacqmin, and J.T. Roberts EORTC Group Study 30851: a phase II study of neoadjuvant chemotherapy in patients with invasive bladder cancer Prog Clin Biol Res 353 1990 213 217
12. T.A. Splinter, L. Denis, H.I. Scher, F.H. Schroder, and O. Dalesio Neoadjuvant chemotherapy of invasive bladder cancer. The prognostic value of local tumor response Prog Clin Biol Res 303 1989 541 547
13. P.K. Schultz, H.W. Herr, and Z.F. Zhang Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up J Clin Oncol 12 1994 1394 1401
14. H.I. Scher, A. Yagoda, and H.W. Herr Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion J Urol 139 1988 470 474
15. R. Millikan, C. Dinney, and D. Swanson Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC J Clin Oncol 19 2001 4005 4013
16. M.E. Nielsen, G.S. Palapattu, and P.I. Karakiewicz A delay in radical cystectomy of >3 months is not associated with a worse clinical outcome BJU Int 100 2007 1015 1020
17. A. Shabsigh, R. Korets, and K.C. Vora Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology Eur Urol 55 2009 164 176
18. S.M. Donat, A. Shabsigh, and C. Savage Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience Eur Urol 55 2009 177 186
19. D. Canter, R. Viterbo, and A. Kutikov Baseline renal function status limits patient eligibility to receive perioperative chemotherapy for invasive bladder cancer and is minimally affected by radical cystectomy Urology 77 2011 160 165
20. C.N. Sternberg, S.M. Donat, and J. Bellmunt Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer Urology 69 Suppl 1 2007 62 79
21. G. Sonpavde, and C.N. Sternberg Neoadjuvant chemotherapy for invasive bladder cancer Curr Urol Rep 13 2012 136 146
22. R. Sylvester, and C. Sternberg The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: what we do not know and why Ann Oncol 11 2000 851 856
23. J.A. Martinez-Pineiro, M. Gonzalez Martin, and F. Arocena Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study J Urol 153 1995 964 973
24. International Collaboration of Trialists, Medical Research Council Advanced Bladder Cancer Working Party, European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group; et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 2011; 29:2171-7.
25. Medical Research Council Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists Lancet 354 1999 533 540
26. H.B. Grossman, R.B. Natale, and C.M. Tangen Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer N Engl J Med 349 2003 859 866
27. H.W. Herr, J.R. Faulkner, and H.B. Grossman Surgical factors influence bladder cancer outcomes: a cooperative group report J Clin Oncol 22 2004 2781 2789
28. E. Scosyrev, B.W. Ely, and E.M. Messing Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710) BJU Int 108 2011 693 699
29. P.F. Bassi, F. Pagano, G. Pappagallo, P. Sperandio, S. Monfardini, and S. Cosciani Neo-adjuvant M-VAC of invasive bladder cancer: G.U.O.N.E. multicenter phase III trial [abstract 567] Eur Urol 33 1998 142
30. P.U. Malmstrom, E. Rintala, R. Wahlqvist, P. Hellstrom, S. Hellsten, and E. Hannisdal Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group J Urol 155 1996 1903 1906
31. A. Sherif, E. Rintala, and O. Mestad Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer - Nordic cystectomy trial 2 Scand J Urol Nephrol 36 2002 419 425
32. W.U. Shipley, K.A. Winter, and D.S. Kaufman Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03 J Clin Oncol 16 1998 3576 3583
33. Advanced Bladder Cancer Meta-analysis Collaboration Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis Lancet 361 2003 1927 1934
34. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data Eur Urol 48 2005 202 206 discussion 205-6
35. E. Winquist, T.S. Kirchner, R. Segal, J. Chin, and H. Lukka Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis J Urol 171 2004 561 569
36. K.A. David, M.I. Milowsky, J. Ritchey, P.R. Carroll, and D.M. Nanus Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base J Urol 178 2007 451 454
37. U. Fedeli, S.A. Fedewa, and E.M. Ward Treatment of muscle invasive bladder cancer: evidence from the National Cancer Database, 2003 to 2007 J Urol 185 2010 72 78
38. B.J. Miles, A.S. Fairey, and M. Eliasziw Referral and treatment rates of neoadjuvant chemotherapy in muscle-invasive bladder cancer before and after publication of a clinical practice guideline Can Urol Assoc J 4 2010 263 267
39. M.P. Porter, M.C. Kerrigan, B.M. Donato, and S.D. Ramsey Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer Urol Oncol 29 2011 252 258
40. C.J. Weight, J.A. Garcia, and D.E. Hansel Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series Cancer 115 2009 792 799
41. R.W. DeVere White, P.N. Lara Jr., and B. Goldman A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219) J Urol 181 2009 2476 2480 discussion 2480-1
42. L.G. Paz-Ares, E. Solsona, and E. Esteban Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study [abstract LBA4518] J Clin Oncol 28 18s 2010
43. A. Dash, J.A. Pettus 4th, and H.W. Herr A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience Cancer 113 2008 2471 2477
44. I. Frank, J.C. Cheville, and M.L. Blute Transitional cell carcinoma of the urinary bladder with regional lymph node involvement treated by cystectomy: clinicopathologic features associated with outcome Cancer 97 2003 2425 2431
45. M. Igawa, S. Urakami, H. Shiina, T. Ishibe, H. Kadena, and T. Usui Long-term results with M-VAC for advanced urothelial cancer: high relapse rate and low survival in patients with a complete response Br J Urol 76 1995 321 324
46. H.G. Juffs, M.J. Moore, and I.F. Tannock The role of systemic chemotherapy in the management of muscle-invasive bladder cancer Lancet Oncol 3 2002 738 747
47. D.I. Quinn, P.J. Creaven, and D. Raghavan Principles of chemotherapy for genitourinary cancer J.P. Richie, A.V. D'Amico, Urological Oncology 2005 Elsevier Philadephia, PA 57 81
48. E.M. Ruggeri, D. Giannarelli, and E. Bria Adjuvant chemotherapy in muscle-invasive bladder carcinoma: a pooled analysis from phase III studies Cancer 106 2006 783 788
49. Advanced Bladder Cancer Meta-analysis Collaboration Adjuvant chemotherapy for invasive bladder cancer (individual patient data) Cochrane Database Syst Rev 2006 CD006018
50. Bajorin DF. Phase III study comparing sequential chemotherapy (AG-ITP) to cisplatin and gemcitabine as adjuvant treatment after cystectomy for transitional cell carcinoma of the bladder. ClinicalTrials.gov Web site. http://clinicaltrials.gov/ct2/show/NCT00014534.
51. F. Cognetti, E.M. Ruggeri, and A. Felici Adjuvant chemotherapy (AC) with cisplatin + gemcitabine (CG) versus chemotherapy (CT) at relapse (CR) in patients (pts) with muscle-invasive bladder cancer (MIBC) submitted to radical cystectomy (RC). An Italian multicenter randomised phase III trial [abstract 5023] J Clin Oncol 2008 26
52. F. Cognetti, E.M. Ruggeri, and A. Felici Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial Ann Oncol 23 2012 695 700
53. Sternberg CN, Sylvester R, Theodore C, et al. Comparison of immediate and delayed adjuvant chemotherapy in treating patients who have undergone a radical cystectomy for stage iii or stage iv transitional cell carcinoma of the bladder urothelium: EORTC 30994. ClinicalTrials.gov Web site. http://clinicaltrials. gov/ct2/show/NCT00028756.
54. R.S. Svatek, S.F. Shariat, and R.E. Lasky The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder Clin Cancer Res 16 2010 4461 4467
55. S.A. Hussain, and N.D. James The systemic treatment of advanced and metastatic bladder cancer Lancet Oncol 4 2003 489 497
56. C.J. Logothetis, D.E. Johnson, and C. Chong Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: an update J Clin Oncol 6 1988 1590 1596
57. P.J. Loehrer Sr., L.H. Einhorn, and P.J. Elson A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study J Clin Oncol 10 1992 1066 1073
58. M. Stockle, W. Meyenburg, and S. Wellek Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study J Urol 148 1992 302 306 discussion 306-7
59. M. Stockle, W. Meyenburg, and S. Wellek Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience J Urol 153 1995 47 52
60. J. Lehmann, M. Retz, and C. Wiemers Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95) J Clin Oncol 23 2005 4963 4974
61. J. Bellmunt, V. Guillem, and L. Paz-Ares Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group J Clin Oncol 18 2000 3247 3255
62. J. Bellmunt, H. von der Maase, and G.M. Mead Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987 J Clin Oncol 30 2012 1107 1113
63. G. Sonpavde, M.M. Khan, and S.P. Lerner Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer J Urol 185 2011 456 461